Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

284 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial.
Duruisseaux M, Baudrin L, Quoix E, Wislez M, Moro-Sibilot D, Coëtmeur D, Monnet I, Mourlanette P, Morère JF, Soria JC, Westeel V, Morin F, Cadranel J. Duruisseaux M, et al. Among authors: quoix e. J Thorac Oncol. 2012 Sep;7(9):1423-31. doi: 10.1097/JTO.0b013e31825ab897. J Thorac Oncol. 2012. PMID: 22767177 Free article. Clinical Trial.
IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype.
Cadranel J, Quoix E, Baudrin L, Mourlanette P, Moro-Sibilot D, Morere JF, Souquet PJ, Soria JC, Morin F, Milleron B; IFCT-0401 Trial Group. Cadranel J, et al. Among authors: quoix e. J Thorac Oncol. 2009 Sep;4(9):1126-35. doi: 10.1097/JTO.0b013e3181abeb5d. J Thorac Oncol. 2009. PMID: 19574932 Free article. Clinical Trial.
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP. Cadranel J, et al. Among authors: quoix e. J Thorac Oncol. 2012 Oct;7(10):1490-502. doi: 10.1097/JTO.0b013e318265b2b5. J Thorac Oncol. 2012. PMID: 22982650 Free article.
Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504.
Cadranel J, Gervais R, Merle P, Moro-Sibilot D, Westeel V, Bigay-Game L, Quoix E, Friard S, Barlesi F, Lethrosne C, Moreau L, Monnet I, Salaun M, Oliviero G, Souquet PJ, Antoine M, Langlais A, Morin F, Wislez M, Zalcman G; Intergroupe Francophone de Cancérologie Thoracique (IFCT). Cadranel J, et al. Among authors: quoix e. Eur Respir J. 2015 Nov;46(5):1440-50. doi: 10.1183/13993003.02358-2014. Epub 2015 Sep 17. Eur Respir J. 2015. PMID: 26381515 Free article. Clinical Trial.
Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.
Pluquet E, Cadranel J, Legendre A, Faller MB, Souquet PJ, Zalcman G, Perol M, Fraboulet G, Oliveiro G, De Fraipont F, Quoix E, Lantuejoul S, Milleron B, Moro-Sibilot D. Pluquet E, et al. Among authors: quoix e. J Thorac Oncol. 2010 Apr;5(4):491-6. doi: 10.1097/JTO.0b013e3181cf0440. J Thorac Oncol. 2010. PMID: 20195171 Free article.
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.
Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Bennouna J, Tredaniel J, Ducoloné A, Lebitasy MP, Baudrin L, Laporte S, Milleron B; Intergroupe Francophone de Cancérologie Thoracique. Quoix E, et al. Lancet. 2011 Sep 17;378(9796):1079-88. doi: 10.1016/S0140-6736(11)60780-0. Epub 2011 Aug 8. Lancet. 2011. PMID: 21831418 Clinical Trial.
An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.
de Fraipont F, Levallet G, Creveuil C, Bergot E, Beau-Faller M, Mounawar M, Richard N, Antoine M, Rouquette I, Favrot MC, Debieuvre D, Braun D, Westeel V, Quoix E, Brambilla E, Hainaut P, Moro-Sibilot D, Morin F, Milleron B, Zalcman G; Intergroupe Francophone de Cancérologie Thoracique. de Fraipont F, et al. Among authors: quoix e. Clin Cancer Res. 2012 May 15;18(10):2976-86. doi: 10.1158/1078-0432.CCR-11-2797. Epub 2012 Mar 20. Clin Cancer Res. 2012. PMID: 22434665 Clinical Trial.
Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials.
Mouillet G, Monnet E, Milleron B, Puyraveau M, Quoix E, David P, Ducoloné A, Molinier O, Zalcman G, Depierre A, Westeel V; Intergroupe Francophone de Cancérologie Thoracique (IFCT). Mouillet G, et al. Among authors: quoix e. J Thorac Oncol. 2012 May;7(5):841-9. doi: 10.1097/JTO.0b013e31824c7d92. J Thorac Oncol. 2012. PMID: 22722786 Free article. Clinical Trial.
Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE.
Wislez M, Barlesi F, Besse B, Mazières J, Merle P, Cadranel J, Audigier-Valette C, Moro-Sibilot D, Gautier-Felizot L, Goupil F, Renault A, Quoix E, Souquet PJ, Madroszyck A, Corre R, Pérol D, Morin F, Zalcman G, Soria JC. Wislez M, et al. Among authors: quoix e. J Clin Oncol. 2014 Apr 20;32(12):1256-61. doi: 10.1200/JCO.2013.53.1525. Epub 2014 Mar 17. J Clin Oncol. 2014. PMID: 24638013 Clinical Trial.
284 results